PRESTIGE BIOPHARMA LIMITED

Other languages Prestige BioPharma Limited

Equities

A950210

KR8702070002

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
8,050 ^KRW	-0.25%		+0.37%	-15.08%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	23-03-21
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	23-03-09
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	22-10-13
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	22-07-26
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	22-06-27
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	22-03-29
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	22-03-11
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	22-03-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW